Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise
January 20, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
- Forxiga Filed for Chronic Heart Failure in Japan: AstraZeneca
January 20, 2020
- Nichi-Iko Quits Herceptin Biosimilar, Focus Now on Avastin Follow-On
January 20, 2020
- Mitsubishi Tanabe to Be Delisted from TSE on February 27
January 20, 2020
- Astellas to Build New API Facility for Prograf in Toyama
January 20, 2020
- Astellas Completes US$3 Billion Audentes Buyout
January 17, 2020
- Asahi Kasei Closes Veloxis Acquisition
January 16, 2020
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
- Orix to Acquire Majority Stake in Generic Drug Maker Kobayashi Kako
January 16, 2020
- ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
January 16, 2020
- Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz
January 15, 2020
- Astellas, Adaptimmune Hook Up on Off-the-Shelf Cell Therapies
January 15, 2020
- Crysvita Filed for Add’l Indication Tumor-Induced Osteomalacia in US
January 15, 2020
- Japan Ethical Drug Sales Slip 1.1% in November 2019: Crecon
January 14, 2020
- Hisamitsu to Establish Subsidiary in Malaysia in October
January 14, 2020
- Eisai Cancer Drug Halaven Goes on Sale in China
January 14, 2020
- Kaken Files Axillary Hyperhidrosis Med in Japan
January 14, 2020
- Healios to Develop Next-Generation Cancer Immunotherapy
January 14, 2020
- Sumitomo Dainippon’s Altavant Picks Up Onspira
January 10, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…